Emerging Infectious Diseases (Jun 2014)

Short-Term Malaria Reduction by Single-Dose Azithromycin during Mass Drug Administration for Trachoma, Tanzania

  • Stephen E. Schachterle,
  • George Mtove,
  • Joshua P. Levens,
  • Emily Clemens,
  • Lirong Shi,
  • Amrita Raj,
  • J. Stephen Dumler,
  • Beatriz Munoz,
  • Shelia West,
  • David J. Sullivan

DOI
https://doi.org/10.3201/eid2006.131302
Journal volume & issue
Vol. 20, no. 6
pp. 941 – 949

Abstract

Read online

Single-dose mass drug administration of azithromycin (AZT) is underway to eliminate trachoma worldwide. Studies in Ethiopia showed a reduction in all-cause childhood deaths after administration. To examine the effect of single-dose AZ MDA on prevalent malaria infections in a large prospective cohort of children and parents in Dodoma Province, Tanzania, we quantified the temporal prevalence of malaria parasitemia by real-time PCR for 6 months after single-dose AZT. In the first month after treatment but not in subsequent months, Plasmodium falciparum infections were reduced by 73% (95% CI 43%–89%) in treatment versus control villages and differences remained significant (p = 0.00497) in multivariate models with village-level random effects. Genetic sequencing of P. falciparum ribosomal L4 protein showed no mutations associated with AZT resistance. AZT mass drug administration caused a transient, 1-month antimalarial effect without selecting for P. falciparum ribosomal L4 resistance mutations in a region with a 10-year history of treating trachoma with this drug.

Keywords